As of 2025-10-24, the Intrinsic Value of Briacell Therapeutics Corp (BCT.TO) is -51.68 CAD. This BCT.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 17.77 CAD, the upside of Briacell Therapeutics Corp is -390.81%.
Based on its market price of 17.77 CAD and our intrinsic valuation, Briacell Therapeutics Corp (BCT.TO) is overvalued by 390.81%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -51.68 - -51.68 | -51.68 | -390.81% |
| DDM - Stable | (74.58) - (249.11) | (161.84) | -1010.8% |
| DDM - Multi | (16.86) - (44.86) | (24.63) | -238.6% |
| Market Cap (mil) | 33.41 |
| Beta | 2.11 |
| Outstanding shares (mil) | 1.88 |
| Enterprise Value (mil) | 33.41 |
| Market risk premium | 5.10% |
| Cost of Equity | 10.72% |
| Cost of Debt | 5.00% |
| WACC | 7.20% |